By performing a detailed analysis of tumor stage, low serum AFP, liver disease etiologies, and pre-HCC diagnosis samples, we aim to provide an in-depth understanding of the applicability of these markers in patients with highly diverse HCC characteristics in these regions. This evidence concerns the gene AFP and hepatocellular carcinoma.